CPT code 78232 represents a nuclear medicine diagnostic study—salivary gland scintigraphy—used to evaluate salivary gland uptake and secretion after intravenous administration of a radiopharmaceutical. The test provides functional information about the parotid and other salivary glands and is used in clinical settings to assess glandular dysfunction, obstructive sialadenitis, or the effects of systemic disease and treatment on salivary function. Nationally, accurate coding of this procedure affects imaging utilization metrics, coverage decisions, and reimbursement for outpatient and hospital-based nuclear medicine services.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise policy and billing summary for CPT code 78232, clinical context explaining when the test is used, and benchmarking elements commonly reviewed by payers and providers. The publication outlines typical sites of service and service type, highlights payer coverage considerations where available, and identifies common modifiers reported with nuclear medicine imaging claims. This material is intended to orient billing staff, radiology administrators, and policy analysts to the clinical purpose and billing context of CPT code 78232 at a national level.

Data not available in the input for payor-specific coverage rules, associated taxonomies, related codes, ICD-10 pairings, or detailed service-line financial benchmarks.